13 June 2017 | News
Under the agreement, Jounce can utilize OncoSec's gene delivery technology to evaluate in vivo efficacy in murine models of intratumorally-delivered therapeutic candidates.
OncoSec Medical Incorporated, a company developing DNA-based intra-tumoral cancer immunotherapies, has engaged in a preclinical agreement through the OncoSec Technology Access Program (TAP) with Jounce Therapeutics, Inc., Cambridge, MA, a company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment.
Established in 2011, OncoSec Medical Incorporated is a San Diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer.
Under the agreement, Jounce can utilize OncoSec's gene delivery technology to evaluate in vivo efficacy in murine models of intratumorally-delivered therapeutic candidates. The agreement includes the GENESIS research generator and proprietary applicators developed for research use.
Through the establishment of these programs, OncoSec benefits from extensive, multi-party characterization and validation of their proprietary, state-of-the art electroporation technologies.
OncoSec has developed a unique delivery technology that will enable Jounce to rapidly assess potential candidates in preclinical models.